Overview
- Health Secretary Robert F. Kennedy Jr., testifying at a Senate Finance hearing Wednesday, claimed cutting a $600 drug to $10 is a “600% reduction,” echoing President Trump’s rhetoric.
- At a White House event Thursday announcing a deal with Regeneron, Kennedy repeated the claim and Trump said there are “two ways of calculating” percentages.
- Independent checks explain that $600 to $10 is a 98.33% cut, and a true 600% reduction would require a negative price, meaning a company would pay customers to take the drug.
- Other officials have defended the framing, with CMS chief Dr. Mehmet Oz calling a drop from $242 to $10 “too high to calculate,” and the White House pointing to U.S.–Australia price gaps that translate to about a 91% cut, not 1,000%.
- Sen. Elizabeth Warren questioned why some brand-name prices on the TrumpRx site still exceed cheaper generics, raising doubts about what patients actually save at the pharmacy counter.